troglitazone has been researched along with Biliary Cirrhosis in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okai, T | 1 |
| Mouri, H | 1 |
| Yamaguchi, Y | 1 |
| Nakanuma, Y | 1 |
| Sawabu, N | 1 |
1 other study available for troglitazone and Biliary Cirrhosis
| Article | Year |
|---|---|
Beneficial hepatic effect of troglitazone in a patient with antimitochondrial antibody-negative primary biliary cirrhosis.
Topics: Autoantibodies; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Cirr | 2002 |